Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study

Christoph U. Correll,1* Josephine Cucchiaro,2 Robert Silva,2 Jay Hsu,2 Andrei Pikalov,2 and Antony Loebel2

1 The Zucker Hillside Hospital, Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks Albert Einstein College of Medicine, Bronx, New York, USA
2 Sunovion Pharmaceuticals Inc., Ft. Lee, New Jersey, USA

Objective. To evaluate the safety and effectiveness of lurasidone in the long-term treatment of patients with schizophrenia.

Methods. Patients who completed a 6-week, double-blind (DB), placebo-controlled trial continued in a 22-month, open-label (OL) study during which they received once-daily, flexible-doses of lurasidone, 40–120 mg. Change in the Positive and Negative Syndrome Scale (PANSS) was analyzed using both observed case (OC) and last observation carried forward (LOCF) analyses.

Results. Of the 251 patients who entered the OL extension, 51.4% completed 6 months, 36.7% completed 12 months, and 26.7% completed 22 months of OL treatment. Treatment with lurasidone was associated with a mean change from DB baseline, in weight of +0.4 kg at Month 12 (n = 99), and +0.8 kg at Month 24 (n = 67; OC analyses). Median change from DB baseline to Month 12 and Month 24, respectively, was -1.0 and -9.0 mg/dL for total cholesterol; 0.0 and -1.0 mg/dL for LDL; +1.0 and -11.0 mg/dL for triglycerides; and 0.0 and +0.1% for HbA1c (OC analyses). The mean PANSS total score was 96.5 at DB baseline and 69.5 at OL baseline. The mean change from DB baseline in the PANSS total score at Month 24 was -43.6 (OC) and -28.4 (LOCF). Thirty-seven patients (14.7%) discontinued due to an adverse event (AE) during OL treatment. Three AEs occurred in ≥10% of patients: schizophrenia (12.4%), akathisia (10.8%), and somnolence (10.8%); and 19.2% reported at least one movement disorder–related AE. Discontinuations due to AEs occurred in 14.8% of patients.

Conclusions. In this 22-month, open-label extension study, treatment with lurasidone was associated with minimal effects on weight, glucose, lipids, and prolactin. Patients demonstrated sustained improvement in the PANSS total score for up to 24 months of lurasidone treatment.

Received 24 June 2015; Accepted 2 October 2015; First published online 6 April 2016

Key words: Atypical antipsychotic, lurasidone, maintenance treatment, safety, schizophrenia.
Introduction

Long-term safety is an important consideration when choosing an antipsychotic agent for maintenance treatment of schizophrenia. This is especially relevant for benefit-risk assessments, since differences in efficacy among available antipsychotic agents appear to be smaller than differences in safety, with differential effects on weight and metabolic parameters, as well as related cardiovascular morbidity, causing the greatest concern.

Lurasidone hydrochloride (HCl), a benzothiazol derivative, is a second-generation antipsychotic agent with potent binding affinity for D₂, 5-HT₂A, and 5HT₇ receptors (antagonist effect); nanomolar affinity for 5HT₁A receptors (partial agonist effect); moderate affinity to 5-HT₂C receptors (antagonist effect); weak affinity (>400 nM) for 5-HT₂C receptors; and little or no affinity for H₁ and M₁ receptors.

The efficacy of lurasidone in the short-term treatment of acute exacerbations of schizophrenia has been demonstrated in a series of double-blind, placebo-controlled short-term studies. Based, in part, on these data, lurasidone received marketing authorization for the treatment of adults with schizophrenia from the Food and Drug Administration in 2010, and from the European Medicines Agency in 2014, as well as from the regulatory authorities in Switzerland, Canada, and Australia. Additionally, lurasidone has received U.S. and Canadian regulatory approval for the treatment of adults with major depressive episodes associated with bipolar I disorder, as either a monotherapy or as adjunctive therapy with lithium or valproate. In short-term, placebo-controlled trials, lurasidone appeared to be associated with particularly low weight gain and metabolic risk potential across these indications compared to what has been reported for several other second-generation antipsychotics (eg, olanzapine, risperidone, quetiapine).

Previous longer-term continuation studies suggest that the efficacy of lurasidone is maintained over 6–12 months with a low potential for adverse effects on weight and metabolic parameters, making it a promising candidate for maintenance treatment. The efficacy of lurasidone in maintaining initial response has been confirmed in a double-blind relapse prevention study in which 12 months of treatment with lurasidone (40–160 mg/day) was associated with a significantly lower risk of relapse compared with quetiapine XR (200–800 mg/day), with a hazard ratio of 0.728, indicating a 27.2% reduction in relapse risk. Treatment with lurasidone was also associated with significantly higher remission rates compared to quetiapine XR (62% vs. 46%; p < 0.05; based on Remission in Schizophrenia Working Group criteria).

We report here the results of an open-label study in which patients diagnosed with an acute exacerbation of schizophrenia who completed an initial 6-week, double-blind, placebo-controlled, fixed-dose trial (lurasidone 40 mg/d, 80 mg/d, 120 mg/d) received 22 months of additional treatment with flexible-doses of lurasidone, 40–120 mg/day. The aim of the current study was to evaluate the safety, tolerability, and effectiveness of lurasidone in the long-term treatment of patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia.

Methods

The current open-label study is the continuation of an initial acute study in which patients, ages 18–75 years inclusive, who met DSM-IV-TR criteria for an acute exacerbation of schizophrenia, and were currently hospitalized, were randomized to 6 weeks of double-blind treatment with once-daily fixed doses of either lurasidone (40 mg, 80 mg, 120 mg) or placebo.

Patients who completed acute, double-blind treatment with either lurasidone or placebo were continued in the current 22-month, open-label extension study. Double-blind study medication was discontinued, and patients were started, open-label, on an 80 mg/day dose of lurasidone. After 7 days of treatment, the dose could be adjusted in 40 mg increments, on a weekly basis, within the flexible dosing range of 40–120 mg/d, as deemed necessary by study investigators. A maximum of 4 dose adjustments were permitted during the 22 months of open-label treatment period. Medication was taken once daily in the morning with a meal or within 30 minutes after eating.

Prior to beginning this open label extension study, an informed consent document explaining study procedures and potential risks was reviewed and signed by all patients. The study protocol, and all related forms and amendments, were approved by an Independent Ethics Committee associated with each study center. The study was conducted in 48 study centers in France (n = 1), India (n = 6), Malaysia (n = 2), Romania (n = 5), Russia (n = 7), Ukraine (n = 6), and the United States (n = 21) in accordance with Good Clinical Practices as required by the International Conference on Harmonisation guidelines and in accordance with ethical principles of the Declaration of Helsinki. An independent Data and Safety Monitoring Board reviewed safety and clinical outcome data at regular intervals during the study.

Assessments

On-treatment assessment visits during the open-label extension phase occurred at monthly intervals up through Month 24, with the exception of a Week 8 visit that occurred 2 weeks after completion of the 6-week
double-blind initial study. To evaluate the long-term safety and tolerability of lurasidone, adverse events (AEs) and vital signs were recorded. Extrapyramidal symptoms were assessed with the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movements Scale (AIMS) at Week 8, Months 3–6, and Months 9, 12, 15, 18, 21, and 24 (or early termination). Samples for fasting laboratory tests (chemistry and hematology panels, lipid panel, glycosylated hemoglobin [HbA1c], prolactin) were obtained at Week 8, Month 3, and every 3 months thereafter. Physical examination was performed at Months 6, 12, 18, and 24 (or early termination). Electrocardiogram (ECG) was recorded at Week 8, and Months 6, 12, 18, and 24 (or early termination). The Fridericia formula was used for calculation of heart rate-adjusted QT interval (QTc).

Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity Scale (CGI-S), and the Montgomery-Åsberg Depression Rating Scale (MADRS). PANSS, CGI-S, and MADRS evaluations were performed at regular intervals.

Statistical methods

The primary objective of this open-label extension phase study was to evaluate the safety and tolerability of lurasidone in patients with schizophrenia. Categorical parameters, for baseline and on-treatment parameters, were summarized by presenting the number (n) and percentage of patients in each category. Continuous parameters were summarized using n, mean, and/or median values. Variability was expressed in terms of standard deviation (SD) or 95% confidence intervals (CIs), which were 2-sided, unless otherwise specified. Number needed to treat (NNT) and within-group effect sizes were calculated. For patients who discontinued prematurely, the last post-baseline measurement was utilized, and was defined as the last observation carried forward (LOCF) for that phase; observed case (OC) analyses were also performed. Criteria for abnormal laboratory and ECG values were specified a priori based on standard values.

In a post-hoc analysis, patients who had an improvement of at least 20% from the acute phase baseline in PANSS total score were defined as responders, while remission was defined using the Remission in Schizophrenia Working Group (RSWG) criteria for symptomatic remission, which requires that a score ≤3 (mild or better) be maintained for at least 6 months on all of the following 8 PANSS items: G5, G9, N1, N4, N6, P1, P2, P3. A Kaplan-Meier estimate of time-to-remission probabilities was calculated for the 2 groups of patients entering the current open-label extension study: acute phase responders and non-responders; differences between the 2 groups were analyzed using the log-rank test. Patients who met remission criteria at open-label baseline were not included in the remission analyses.

Findings

A total of 496 patients were randomized in the core acute study, of whom 328 (66.1%) completed 6 weeks of double-blind treatment with one of 3 doses of lurasidone, or placebo. Of those completers, 251 (76.5%) elected and were eligible to continue in the current open-label extension study, 62 from the lurasidone 40 mg group, 65 from the lurasidone 80 mg group, 65 from the lurasidone 120 mg group, and 59 from the placebo group (Figure 1). This comprised the population used for both safety and efficacy analyses (1 patient did not
receive a dose of lurasidone and was excluded from the analyses). A total of 36.7% of patients completed 12 months of open-label extension phase treatment, and 26.7% completed the full 22 months of extension treatment. Withdrawal of consent was the most common reason for discontinuation, followed by insufficient clinical response, discontinuation due to an adverse event, lost to follow-up, protocol violation, and miscellaneous other reasons (Figure 1).

Baseline demographic and clinical characteristics of the safety population are summarized in Table 1. Patients who were switched from placebo to lurasidone (versus patients who continued on lurasidone) were more likely to be male (73% vs 62%) and were more likely to have had 4 or more hospitalizations (64% vs 56%; Table 1); other baseline variables were approximately similar for each group.

The mean (SD) daily dose of lurasidone for all patients was 87.8 (19.8) mg. The proportion of patients using modal daily doses of 40 mg, 80 mg, and 120 mg, respectively, was similar at 6 months (13%, 42%, 45%), 1 year (15%, 38%, 47%), and 2 years (16%, 39%, 45%). Of the 191 patients for whom compliance data were available, all but 1 met a priori compliance criteria throughout the study of (pill counts within a range of 75% to 125% of prescribed dosing).

### Safety

#### Adverse events

Approximately two-thirds of patients reported one or more treatment-emergent adverse events (AEs) during 22-month open-label treatment (Table 2). The most frequently reported AEs were schizophrenia, akathisia, and somnolence (Table 2). Overall, 9.2% of patients reported an AE rated as severe; the incidence of a rating as severe was <2% for all individual events.

In general, initial double-blind treatment assignment did not appear to influence the frequency of AEs during open-label treatment, with the exception of 3 AEs that were reported with a higher frequency in the subgroup switched from placebo (in the double-blind phase) to lurasidone when compared to patients continuing on lurasidone, respectively: nausea (18.6% vs. 5.2%), vomiting (16.9% vs. 6.3%), and anxiety (16.9% vs. 4.7%).

A total of 49 patients (19.6%) reported one or more AEs categorized as “serious” during 24 months of open-label treatment. The only serious AEs reported by ≥1% of patients were schizophrenia (17%), akathisia (9%), and somnolence (9%).

### Table 1: Baseline characteristics (safety population)

<table>
<thead>
<tr>
<th></th>
<th>Lurasidone (acute) and lurasidone (extension) (N = 191)</th>
<th>Placebo (acute) and lurasidone (extension) (N = 59)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>Male</td>
<td>119</td>
<td>62</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>95</td>
<td>50</td>
</tr>
<tr>
<td>Black/African American</td>
<td>56</td>
<td>29</td>
</tr>
<tr>
<td>Asian</td>
<td>38</td>
<td>20</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Ethnicity, Hispanic/Latino</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Prior hospitalizations: ≥4</td>
<td>107</td>
<td>56</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>38.3</td>
<td>10.7</td>
<td>38.8</td>
<td>10.0</td>
</tr>
<tr>
<td>Age at onset of illness, years</td>
<td>25.1</td>
<td>8.6</td>
<td>24.2</td>
<td>8.5</td>
</tr>
<tr>
<td>Duration of illness, years</td>
<td>12.7</td>
<td>9.7</td>
<td>14.2</td>
<td>10.4</td>
</tr>
<tr>
<td>Duration of current episode, days</td>
<td>52.4</td>
<td>12.3</td>
<td>52.8</td>
<td>14.4</td>
</tr>
<tr>
<td>PANSS total score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double-blind baseline</td>
<td>96.8</td>
<td>10.4</td>
<td>95.5</td>
<td>10.1</td>
</tr>
<tr>
<td>Open-label baseline</td>
<td>69.8</td>
<td>16.2</td>
<td>68.4</td>
<td>17.4</td>
</tr>
<tr>
<td>CGI-S score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double-blind baseline</td>
<td>4.9</td>
<td>0.6</td>
<td>4.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Open-label baseline</td>
<td>3.4</td>
<td>0.8</td>
<td>3.5</td>
<td>0.9</td>
</tr>
<tr>
<td>MADRS total score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double-blind baseline</td>
<td>10.6</td>
<td>6.7</td>
<td>11.4</td>
<td>6.0</td>
</tr>
<tr>
<td>Open-label baseline</td>
<td>6.1</td>
<td>5.3</td>
<td>6.2</td>
<td>5.0</td>
</tr>
</tbody>
</table>

Lurasidone (acute) and (extension): Treated with lurasidone during double-blind acute study, then continued on lurasidone during open-label extension study. Placebo (acute) and lurasidone (extension): Treated with placebo during double-blind acute study, then switched to lurasidone during open-label extension study.

PANSS: Positive and Negative Symptom Scale; CGI-S: Clinical Global Impression scale–Severity; MADRS: Montgomery–Åsberg Depression Rating Scale; SD: standard deviation.
patients were schizophrenia (10.0%) and psychotic disorder (2.8%). One suicide attempt (overdose of antihistamine, doxylamine, taken for insomnia) occurred. The event was judged by the investigator to be “unlikely related” to study drug; the patient recovered. A second suicide attempt (ingestion of a large amount of alcohol) was judged to be non-serious, “unrelated” to study drug, and did not result in hospitalization. There were 2 deaths during the open-label extension phase: 1 due to traumatic brain injury suffered in a car accident and 1 due to burns from a kitchen fire. Both were considered unrelated to study medication. Five patients experienced serious AEs that were judged to be related or probably related to lurasidone: relapse/exacerbation of schizophrenia (n = 3 patients), akathisia (n = 2), Parkinsonism (n = 1).

Physical examination and vital signs

There were no clinically significant treatment-emergent changes during open-label treatment with lurasidone in pulse rate, systolic or diastolic blood pressure, or body temperature.

Extrapyramidal symptoms

The proportion of patients reporting the EPS-related adverse events of Parkinsonism (6.4%) and akathisia (10.8%) is summarized in Table 2. There was a low incidence of other EPS-related symptoms such as tremor (2.4%) and dystonia (1.6%). Four patients (1.6%) discontinued study medication due to akathisia and 1 (0.4%) due to tardive dyskinesia. The majority of patients remained unchanged from open-label baseline to LOCF-endpoint in their scores on the AIMS (91.5%), the BARS Global Clinical Assessment of Akathisia (80.9%), and the SAS (83.4%). Among patients reporting a change, a similar proportion reported categorical worsening compared to improvement on the AIMS (4.3% vs 4.3%, respectively) and the BARS Global Clinical Assessment of Akathisia (10.2% vs 9.8%, respectively); while a higher proportion reported categorical worsening compared to improvement on the SAS (14.5% vs 2.1%, respectively). Overall, 54 patients (21.6%) were treated with an anticholinergic medication; other classes of concomitant medication used by at least 10% of patients consisted of anxiolytics (36.8%), sedative-hypnotics (22.4%), and nonsteroidal anti-inflammatory drugs (11.2%).

Body weight, body mass index (BMI), and waist circumference

A small increase in mean weight was observed during lurasidone treatment at Months 12 and 24 in both the total sample and in the lurasidone continuation group (Table 3; OC analysis). At Month 12, clinically significant (≥7% change) weight gain occurred in 14.1% of patients (n = 99) in the total sample (observed case analysis), and clinically significant weight loss occurred in 12.1%; at Month 24, clinically significant weight gain occurred in 22.4% of patients (n = 67), and clinically significant weight loss occurred in 11.9%. No clinically significant mean increases were observed in either BMI or waist circumference at Months 12 or 24 (Table 3; OC analysis). For the total sample, a shift in BMI from underweight/normal to overweight occurred in 6.4% of patients (no patients became obese), while 4.7% shifted from overweight/obese to normal weight (LOCF-endpoint analysis).

Metabolic parameters

Overall, there were no clinically meaningful median changes from double-blind baseline in fasting lipid
parameters (total cholesterol, triglycerides, LDL or HDL cholesterol) or measures of (non-fasting) glycemic control (glucose, HbA1c) during 24 months of treatment with lurasidone (Table 3). From double-blind baseline to Month 24, a smaller proportion of patients had a categorical shift from normal-to-high values compared to high-to-normal values for total cholesterol (6.8% vs. 16.0%), LDL cholesterol (9.6% vs. 6.8%), and for triglycerides (8.2% vs. 9.1%; Figure 2). A higher proportion of patients had a categorical shift from normal-to-high values compared to high-to-normal values for HbA1c (6.1% vs. 4.7%; Figure 2).

### Prolactin and other laboratory values

For the total sample, there were minimal changes from double-blind baseline in mean and median prolactin levels at Months 12 and 24 (Table 3). Median reductions in prolactin from double-blind baseline were somewhat greater for males versus females at Month 12 (-1.7 vs. -0.1 ng/mL) and Month 24 (-1.6 vs. -0.6 ng/mL). When change was calculated from open-label baseline for the total sample, small reductions occurred in mean and median prolactin levels at Months 12 and 24; median reductions in prolactin were greater for males versus females.
females at both assessment time-points. A treatment-emergent shift from normal (at double-blind baseline) to high (abnormal) prolactin levels occurred in 10 males (7.2%; criterion for high value >17.7 ng/mL) and 10 females (12.5%; criterion for high value >29.2 ng/mL). No patients in any treatment group discontinued study medication due to elevated prolactin.

There was no evidence for hepatic toxicity during 24 months of treatment with lurasidone. There were minor, clinically insignificant changes from open-label baseline to LOCF-endpoint in ALT and AST. Four patients (1.7%) had a markedly abnormal ALT and 3 patients (1.3%) had a markedly abnormal AST during open-label treatment; the abnormalities resolved in all but 1 subject, and none resulted in discontinuation from the study medication. There were no other clinically meaningful changes in mean chemistry or hematology lab values during the course of the study.

**ECG**

There were no clinically meaningful changes in mean ECG parameters during open-label treatment with lurasidone. The mean (SD) change from baseline in QTcF was 4.7 (17.8) msec (LOCF-endpoint). No patients had a QTcF interval of >500 msec at any time from double-blind baseline to Month 24. For this overall treatment period, 2 patients (0.9%) had ≥60 msec increase in QTcF interval.

**Efficacy**

Among patients who entered the current extension phase study, the initial 6 weeks of double-blind treatment was associated with comparable levels of improvement in mean PANSS total score in the group randomized to lurasidone (-27.0) and the group randomized to placebo (-27.1). For the combined treatment groups, the mean PANSS total score decreased from 96.5 to 69.5. Over the course of 24 months, treatment with lurasidone was associated with continued improvement beyond what was achieved in the PANSS total and subscale scores after the initial 6 weeks of double-blind treatment (Figure 3; OC analysis). Continued improvement was observed, both in patients initially randomized, in the acute phase, to lurasidone, and to placebo (Table 4). Improvement slightly favored patients treated with lurasidone during the initial double-blind phase.

For month 6 and month 12 completers (OC analysis), the proportion of patients who met full RSWG criteria for remission was 62% at 6 months and 67% at 12 months. When dropouts were included (LOCF-analysis), the proportion of patients who met full RSWG criteria for remission was 33% at 6 months and 28% at 12 months. Remission was not assessed beyond 12 months due to small sample sizes. A Kaplan–Meier analysis showed a higher probability of achieving

**FIGURE 2.** Proportion of patients treated with lurasidone whose laboratory values showed a double-blind baseline to endpoint shift between low/normal and high. Criteria for shift to high values were as follows: total cholesterol (>200 ng/mL), triglycerides (>203 ng/mL), glucose (≥100 mg/dL), HbA1c (>6%). Glucose measurements were fasting, based on patient report; no additional measures were taken to confirm fasting status.

**FIGURE 3.** Change from double-blind baseline in PANSS total and subscale scores during 24 months of lurasidone treatment (OC analysis).
remission in the group of patients who were responders at open-label baseline compared with nonresponders (Figure 4; log-rank chi square, 7.63; \(P < 0.01\)). Nonetheless, among nonresponders at open-label baseline, 41% met RSWG criteria for remission at Month 6 and 47% at Month 12 (OC analysis). Conversely, 4.0% of responders lost their response by 6 months, and 2.9% at 12 months, defined as falling below the 20% PANSS total score improvement threshold.

**Discussion**

We report here the results of an open-label study in which patients diagnosed with an acute exacerbation of schizophrenia who completed an initial 6-week, double-blind, placebo-controlled, fixed-dose trial of lurasidone received 22 months of continuation treatment with flexible doses of lurasidone, 40–120 mg/day. The combined study treatment of up to 24 months represents the longest exposure to lurasidone in a controlled clinical trial that has been reported to date. Of the 251 patients who entered this extension study, 27% completed 22 months of extension treatment. The observed rate of attrition at endpoint (73%) is consistent with results from other studies of oral antipsychotics with durations \(\geq 18\) months.\(^{27,28}\) Withdrawal of consent (24%) was the most common reason cited for early discontinuation, with adverse effects leading to treatment discontinuation cited in 14.8% of patients.

The group of patients who continued into the current continuation study had shown marked improvement during the initial 6-week double-blind phase, as demonstrated by a mean decrease in PANSS total score from 96.5 to 69.5. The magnitude of acute improvement was very similar regardless of initial double-blind treatment assignment, likely reflecting a favorable selection bias in the placebo group (i.e., completers who improved sufficiently that they were willing to consider entering an extension study). Sustained response was observed in the majority of patients during 22 months of additional lurasidone treatment. A small number of responders at extension study baseline reported loss of response at Months 6 and 12 (4.0% and 2.9%, respectively). These results were consistent with other studies that have formally evaluated relapse prevention efficacy associated with lurasidone.\(^{19,29}\)

**TABLE 4. Mean change in efficacy measures at month 24: observed case and LOCF-endpoint analysis**

<table>
<thead>
<tr>
<th></th>
<th>Lurasidone (acute) and Lurasidone (extension)</th>
<th>Placebo (acute) and Lurasidone (extension)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observed (n = 52) LOCF-endpoint (n = 179)</td>
<td>Observed (n = 17) LOCF-endpoint (n = 56)</td>
</tr>
<tr>
<td>Mean (SD) 95%-CI</td>
<td>Mean (SD) 95%-CI</td>
<td>Mean (SD) 95%-CI</td>
</tr>
<tr>
<td>PANSS total score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from DB baseline</td>
<td>-43.6 (15.9) -48.0, -39.1</td>
<td>-31.5, -25.4</td>
</tr>
<tr>
<td>Change from OL baseline</td>
<td>-13.1 (16.9) -17.8, -8.4</td>
<td>-9.7 (13.8) -16.8, -2.6</td>
</tr>
<tr>
<td>PANSS positive subscore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from DB baseline</td>
<td>-14.6 (5.0) -16.0, -13.2</td>
<td>-12.1 (4.3) -14.3, -9.9</td>
</tr>
<tr>
<td>Change from OL baseline</td>
<td>-3.8 (4.4) -5.0, -2.6</td>
<td>-3.4 (4.3) -5.0, -1.1</td>
</tr>
<tr>
<td>PANSS negative subscore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from DB baseline</td>
<td>-8.4 (5.5) -10.0, -6.9</td>
<td>-8.0 (4.5) -10.3, -5.7</td>
</tr>
<tr>
<td>Change from OL baseline</td>
<td>-3.0 (5.1) -4.4, -1.6</td>
<td>-2.6 (4.5) -5.0, -0.3</td>
</tr>
<tr>
<td>CGI-Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from DB baseline</td>
<td>-2.3 (0.8) -2.5, -2.1</td>
<td>-2.0 (0.8) -2.4, -1.6</td>
</tr>
<tr>
<td>Change from OL baseline</td>
<td>-0.5 (0.7) -0.7, -0.3</td>
<td>-0.4 (0.7) -0.7, 0.0</td>
</tr>
<tr>
<td>MADRS total score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from DB baseline</td>
<td>-6.9 (6.7) -8.8, -5.0</td>
<td>-5.4 (7.3) -9.3, -1.5</td>
</tr>
<tr>
<td>Change from OL baseline</td>
<td>-1.8 (4.9) -3.1, -0.4</td>
<td>+2.7 (8.1) -0.2, +7.0</td>
</tr>
</tbody>
</table>
| PANSS: Positive and Negative Symptom Scale; CGI-S: Clinical Global Impression scale-Severity; MADRS: Montgomery-Åsberg Depression Rating Scale; DB: double-blind; OL: open-label; CI: confidence interval; SD: standard deviation.

**FIGURE 4.** Kaplan–Meier estimate of the probability of achieving full RSWG remission during 22 months of extension phase treatment: results by responder status at open-label baseline.

![Log-rank P<0.01](https://doi.org/10.1017/S1092852915000917) Published online by Cambridge University Press
In the current study, a high proportion of patients met full RSWG criteria for remission who completed 6 months (62%) and 12 months (67%) of treatment with lurasidone. RSWG criteria are rigorous and require 6 months of sustained symptomatic remission.19 These remission rates are very similar to the 61.9% remission rates reported after 12 months of treatment with lurasidone in the relapse prevention trial cited above.19 In an LOCF analysis, with dropouts included, RSWG remission rates in the current study were 28% at 12 months. By comparison, in the CATIE study,30 RSWG remission criteria were met by 11.7% of patients at 18 months. The higher remission rates in the current study are likely attributable to the shorter observation period (12 vs 18 months), but may also be due to differences in study populations, as well as differences in antipsychotic treatment regimens (including medication switching).

In up to 24 months of extension-phase treatment, lurasidone was generally well-tolerated, with the majority of adverse events in the mild-to-moderate severity range. Importantly, long-term treatment with lurasidone was associated with a low potential for adverse effects on weight, lipids, and glycemic indices. These results confirm and extend the findings of multiple short-term9–13 and two 1-year studies,17,19 and are consistent with the safety and tolerability data summarized in the U.S. product label.14

High rates of metabolic syndrome have been observed in schizophrenia, ranging up to 50% in some large samples,6,27 with a significant excess in cardiovascular mortality risk.31–33 There is growing concern that the cardiovascular mortality risk may be undergoing an iatrogenic increase since the introduction of second-generation antipsychotics.7,33–35 The current long-term data provide considerable evidence that treatment with lurasidone is associated with a low potential for adverse effects on weight and metabolic parameters. In light of comparative meta-analyses,1 cardiometabolic safety has been established as an important consideration when choosing an antipsychotic.1,3,36

Consistent with previous studies,17 treatment with lurasidone was associated with minimal changes in prolactin levels, though there was a high degree of variability in prolactin levels, with a treatment-emergent shift from normal-to-high prolactin levels occurring in 7.2% of males and 12.5% of females. Lurasidone appears to have a modest effect on prolactin that is intermediate between aripiprazole and risperidone.1,37 The incidence of akathisia was 10.8%, similar to rates reported in previous 12-month trials.13,17 Approximately 1 out of 5 patients treated with lurasidone received anticholinergic medication. As expected, patients treated initially with placebo and switched to lurasidone for the first time reported more frequent use of anticholinergic medication. Change in movement disorder signs or symptoms as measured by change in SAS, BARS, and AIMS scores was generally absent or mild.

The major limitation of the current study was the absence of a randomized, double-blind, active comparator to provide a benchmark for concurrent evaluation of both efficacy and safety outcomes. A second limitation, common to studies with durations of this length, is the high attrition rate, which should be taken into consideration while interpreting results of this study.

Conclusions

In this open-label extension study, the majority of patients demonstrated sustained improvement in the PANSS total score during up to 24 months of treatment with flexible doses of lurasidone in the range of 40–120 mg, administered once-daily. Rates for loss of response were low, and approximately two-thirds of patients completing 12 months of treatment met stringent remission criteria. Long-term treatment with lurasidone was associated with a low potential for adverse effects on weight, lipids, and glycemic indices. Taken together with findings from previous studies, lurasidone appears to be a safe and effective option for the long-term treatment of schizophrenia.

Disclosures

Christoph Correll has the following disclosures: AbbVie, consultant/advisor, honoraria; Bristol-Myers Squibb, researcher, research grant; Genetech, consultant/advisor, honoraria; Intra-Cellular Therapies, consultant/advisor, honoraria; Janssen Pharmaceuticals, consultant/advisor, honoraria; Actavis, consultant/advisor, honoraria; honoraria; Lundbeck Pharmaceuticals, consultant/advisor, honoraria; MEDACorp, consultant/advisor, honoraria; Otsuka America Pharmaceuticals, consultant/advisor, honoraria; Sunovion Pharmaceuticals, consultant/advisor, honoraria; Takeda Pharmaceuticals, consultant/advisor, honoraria; Gerson Lehrman Group, consultant/advisor, honoraria; Medscape, consultant/advisor, honoraria; ProPhase, consultant/advisor, honoraria. Josephine Cucchiaro has the following disclosure: Sunovion, employee, salary. Jay Hsu has the following disclosure: Sanovion, employee, salary. Andrei Pikalov has the following disclosure: Sanovion, employee, salary. Anthony Loebel has the following disclosure: Sanovion, employee, salary.
REFERENCES:


